Format
Sort by

Send to

Choose Destination

Search results

Items: 7

1.

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA.

Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4.

2.

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α.

Gits CM, van Kuijk PF, de Rijck JC, Muskens N, Jonkers MB, van IJcken WF, Mathijssen RH, Verweij J, Sleijfer S, Wiemer EA.

BMC Cancer. 2014 Jun 13;14:429. doi: 10.1186/1471-2407-14-429.

3.

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C, Mathijssen RH, den Bakker MA, Verweij J, Sleijfer S, Wiemer EA.

Int J Cancer. 2014 Jul 15;135(2):348-61. doi: 10.1002/ijc.28694. Epub 2014 Jan 16.

4.

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.

Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, van Ijcken WF, Wozniak A, Sciot R, Rutkowski P, Schöffski P, Taguchi T, Mathijssen RH, Verweij J, Sleijfer S, Debiec-Rychter M, Wiemer EA.

Br J Cancer. 2013 Sep 17;109(6):1625-35. doi: 10.1038/bjc.2013.483. Epub 2013 Aug 22.

5.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
6.

MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation.

Zubakov D, Boersma AW, Choi Y, van Kuijk PF, Wiemer EA, Kayser M.

Int J Legal Med. 2010 May;124(3):217-26. doi: 10.1007/s00414-009-0402-3. Epub 2010 Feb 10.

7.

Mismatch repair and treatment resistance in ovarian cancer.

Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM.

BMC Cancer. 2006 Jul 31;6:201.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk